Katelyn Rodgers
Primary Care · Denver, CONPI 1629728878
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 31.9% of the total. 2024 is the largest year on record at $611, more than ten times the $49 reported in 2022.
Across 53 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$325
- Novo Nordisk$168
- AstraZeneca$115
- Lilly USA, LLC$65
- Pfizer$62
- GSK$58
- plus $227 from 10 others
What the payments were for
- Food & beverage$1,020100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 16 | $325 |
| Novo Nordisk | 10 | $168 |
| AstraZeneca | 6 | $115 |
| Lilly USA, LLC | 4 | $65 |
| Pfizer | 3 | $62 |
| GSK | 2 | $58 |
| Exact Sciences | 2 | $40 |
| Novartis | 2 | $33 |
| Viiv Healthcare Company | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Amgen | 1 | $21 |
| Nevro Corp. | 1 | $17 |
| Seqirus USA Inc | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Merck | 1 | $14 |
How this compares
$1,020 in reported general payments places this provider in the 75th percentile of 112 primary care providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 146 | $23,060 |
| Buprenorphine Hcl | 24 | $793 |
| Atorvastatin Calcium | 45 | $483 |
| Levothyroxine Sodium | 32 | $326 |
| Gabapentin | 30 | $326 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $180 |
| Metoprolol Succinate | 14 | $179 |
| Lisinopril | 25 | $133 |
| Rosuvastatin Calcium | 23 | $132 |
| Losartan Potassium | 19 | $95 |
| Amlodipine Besylate | 15 | $89 |
| Azithromycin | 20 | $71 |
| Metformin Hcl | 11 | $66 |
| Trazodone Hcl | 15 | $40 |
Paid to pharmacies, not to this prescriber.
Other primary care in Denver
- Kaitlin KrausDenver$16K
- Mary CarrascoDenver$2K
- Jacki DegolyerDenver$2K
- Loraine van SlykeDenver$1K
- Teresa SalazarDenver$1K
- Melanie SpottsDenver$857
- Laura VillasenorDenver$802
- Lisa LumleyDenver$593
- Danielle HamstraDenver$359
- Belinda HigaDenver$299
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.